Legal Representation
Attorney
Christina M. Licursi
USPTO Deadlines
Next Deadline
1286 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2009-01-20)
Due Date
January 20, 2029
Grace Period Ends
July 20, 2029
Application History
46 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 1, 2019 | INNP | P | PARTIAL INVALIDATION PROCESSED BY THE IB |
| Sep 28, 2019 | INPC | P | INVALIDATION PROCESSED |
| Sep 28, 2019 | INPS | P | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB |
| Sep 25, 2019 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Mar 7, 2019 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Jan 25, 2019 | 71.P | O | REGISTERED - PARTIAL SEC 71 ACCEPTED |
| Jan 25, 2019 | NA71 | E | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED |
| Jan 18, 2019 | ES71 | I | TEAS SECTION 71 RECEIVED |
| Jan 20, 2018 | REM4 | E | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED |
| Jun 8, 2017 | RNWL | P | INTERNATIONAL REGISTRATION RENEWED |
| May 19, 2016 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Feb 6, 2015 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Feb 6, 2015 | C75A | O | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. |
| Feb 6, 2015 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED |
| Jan 20, 2015 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED |
| Dec 4, 2014 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Nov 27, 2014 | CHLD | M | CHANGE OF OWNER RECEIVED FROM IB |
| May 28, 2014 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| May 5, 2013 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Apr 15, 2011 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| May 4, 2009 | FIMP | P | FINAL DISPOSITION PROCESSED |
| May 4, 2009 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Apr 20, 2009 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Jan 20, 2009 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Nov 4, 2008 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 15, 2008 | NPUB | O | NOTICE OF PUBLICATION |
| Sep 30, 2008 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Sep 29, 2008 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sep 26, 2008 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Sep 26, 2008 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Sep 26, 2008 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 26, 2008 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Mar 31, 2008 | CNFR | O | FINAL REFUSAL MAILED |
| Mar 28, 2008 | CNFR | R | FINAL REFUSAL WRITTEN |
| Mar 20, 2008 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 20, 2008 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED |
| Mar 19, 2008 | ALIE | A | ASSIGNED TO LIE |
| Mar 3, 2008 | I | PAPER RECEIVED | |
| Sep 20, 2007 | RFNT | P | REFUSAL PROCESSED BY IB |
| Aug 31, 2007 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Aug 31, 2007 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Aug 31, 2007 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Aug 30, 2007 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 17, 2007 | NWAP | I | NEW APPLICATION ENTERED |
| Aug 17, 2007 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 16, 2007 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 001
Plant biopolymers, namely, chitin, chitosans, chitin-glucan and derivatives of these products, for industrial and scientific applications
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Pharmaceutical and veterinary preparations made from biopolymers, used with other compounds to treat bleeding, wound, tissue disorders, inflammative disorders, immune disorders, degenerative disorders, cancer, neurological disorders, eye disorders, infections, as cell culture media, as excipients for systems involving the controlled release of actives, and used as a biomaterial component of medical devices for the treatment of wounds and burns, used in wound management, haemostatic systems, surgical systems, ophthafmologic devices, tissue engineering devices, cartilage substitutes, bone substitutes, skin reconstruction devices, periodontal products, vascular systems, and used in drug delivery systems in nanoparticles, microspheres, solutions, hydrogels, used in oral delivery, local delivery, mucosal delivery, nasal delivery, ocular delivery, transdermal delivery, intratumoral delivery
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Translation
The term "KIOMEDINE" appearing in the mark has no meaning in a foreign language.
Classification
International Classes
001
005
USPTO Documents
Loading USPTO documents...